- Novo NordiskWegovy maker Novo Nordisk said it is teaming up with Hims & Hers Health to sell its weight-loss drugs through the telehealth company’s platform, bringing an end to a legal dispute between the two companies. Hims & Hers shares jumped 47% Monday, while Novo Nordisk shares were up 1.7%. Hims & Hers will no longer advertise compounded versions of GLP-1 drugs—the class of medicines to which Wegovy and Ozempic belong—on its platform, Novo Nordisk said. Compounded drugs are alternative versions of prescription drugs made by specialized pharmacies. Hims & Hers in February countered with a compounded pill version of the drug’s main ingredient, semaglutide, prompting Novo Nordisk’s lawsuit.

Source: Wall Street Journal March 09, 2026 13:08 UTC